<DOC>
	<DOCNO>NCT00272103</DOCNO>
	<brief_summary>This study aim determine efficacy optimal dose prokinetic itopride treatment patient functional dyspepsia . The study test patient functional dyspepsia hypothesis itopride superior placebo regard improvement symptom .</brief_summary>
	<brief_title>Itopride Functional Dyspepsia : Dose Finding Study</brief_title>
	<detailed_description>Treatment patient functional dyspepsia remain unsatisfactory . We assess efficacy Itopride , D2 antagonist acetylcholinesterase effect patient functional dyspepsia . Patients functional dyspepsia randomize Itopride ( 50 , 100 200 mg tid ) placebo . After 8 week treatment , three primary efficacy endpoint analyze : ) change severity functional dyspepsia symptom ( assessed Leeds Dyspepsia Questionnaire ) , b ) patient â€™ global assessment efficacy ( proportion patient symptom-free markedly improve ) c ) improvement pain and/or fullness least one grade 5-grade scale .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Diagnosis functional dyspepsia ( Rome criterion ) structural biochemical abnormality explain symptom , concomitant symptom gastroesophageal reflux disease irritable bowel syndrome dominate clinical picture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>functional dyspepsia</keyword>
	<keyword>non ulcer dyspepsia</keyword>
	<keyword>drug treatment</keyword>
</DOC>